News and Analysis
Nature Reviews Drug Discovery 2, 257-258 (April 2003) | doi:10.1038/nrd1068
Fresh from the Pipeline: Teriparatide
Carilee Berg1, Kat Neumeyer1 & Peter Kirkpatrick2
Top of page
Abstract
Teriparatide (Forteo; Eli Lilly), a recombinant form of the 34 amino-terminal amino acids of human parathyroid hormone, was approved by the US FDA in November 2002 for the treatment of osteoporosis. As the first agent to stimulate bone formation, rather than just reduce bone loss, what impact is it likely to have on the osteoporosis drug market?
Author affiliations
- Carilee Berg and Kat Neumeyer are at Decision Resources Inc., 260 Charles Street, Waltham, Massachusetts 020453, USA.
- Peter Kirkpatrick is a Senior Editor at Nature Reviews Drug Discovery.
Correspondence to: Carilee Berg1 Email: cberg@dresources.com
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated NEWS AND VIEWS |
